Bosutinib hydrate
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 333068

CAS#: 918639-08-4 (hydrate)

Description: Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib was approved in 2012

Chemical Structure

img
Bosutinib hydrate
CAS# 918639-08-4 (hydrate)
Instruction

Theoretical Analysis

MedKoo Cat#: 333068
Name: Bosutinib hydrate
CAS#: 918639-08-4 (hydrate)
Chemical Formula: C26H31Cl2N5O4
Exact Mass: 0.00
Molecular Weight: 548.465
Elemental Analysis: C, 56.94; H, 5.70; Cl, 12.93; N, 12.77; O, 11.67

Price and Availability

Size Price Availability Quantity
200mg USD 150 2 Weeks
500mg USD 250 2 Weeks
1g USD 450 2 Weeks
2g USD 750 2 Weeks
5g USD 1650 2 Weeks
10g USD 2950 2 Weeks
Bulk inquiry

Related CAS #: 918639-08-4 (hydrate)   380843-75-4 (free base)   2211052-79-6 (besylate)    

Synonym: SKI606; SKI 606; SK-I606. SK 606; SK-606; SK606; KIN 001-160; KIN001-160; KIN-001-160; KIN 001160; KIN-001160; KIN001160; Bosutinib; Brand name: Bosulif.

IUPAC/Chemical Name: 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile hydrate

InChi Key: BXPOSPOKHGNMEP-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H29Cl2N5O3.H2O/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27;/h11-14,16H,4-10H2,1-3H3,(H,30,31);1H2

SMILES Code: N#CC1=C(NC2=CC(OC)=C(Cl)C=C2Cl)C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=C1.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 548.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cui Z, Li B, Zhang Y, He J, Shi X, Wang H, Zhao Y, Yao L, Ai D, Zhang X, Zhu Y. Inhibition of Soluble Epoxide Hydrolase Attenuates Bosutinib-Induced Blood Pressure Elevation. Hypertension. 2021 Nov;78(5):1527-1540. doi: 10.1161/HYPERTENSIONAHA.121.17548. Epub 2021 Oct 4. PMID: 34601968; PMCID: PMC8516812.


2: Yilmaz S, Alkan T, Ballar Kirmizibayrak P. A new underlying mechanism for the neuroprotective effect of bosutinib: Reverting toxicity-induced PARylation in SIN1-mediated neurotoxicity. J Biochem Mol Toxicol. 2021 Sep 14:e22915. doi: 10.1002/jbt.22915. Epub ahead of print. PMID: 34519134.


3: Mahdavi KD, Jordan SE, Barrows HR, Pravdic M, Habelhah B, Evans NE, Blades RB, Iovine JJ, Becerra SA, Steiner RA, Chang M, Kesari S, Bystritsky A, O'Connor E, Gross H, Pereles FS, Whitney M, Kuhn T. Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor. Neurol Clin Pract. 2021 Jun;11(3):e294-e302. doi: 10.1212/CPJ.0000000000000918. PMID: 34484904; PMCID: PMC8382351.


4: Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina AG, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes J, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. Blood. 2021 Aug 18:blood.2020009984. doi: 10.1182/blood.2020009984. Epub ahead of print. PMID: 34407542.


5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Bosutinib. 2021 Aug 16. PMID: 29999903.


6: Nakajima R, Matsuo T, Sumiyoshi R, Saito S, Yamamoto T, Matsumoto K, Akiyama N, Ooi J, Ota Y, Shirafuji N, Tashiro H. Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib. Br J Haematol. 2021 Aug 10. doi: 10.1111/bjh.17771. Epub ahead of print. PMID: 34378212.


7: Muresan B, Mamolo C, Cappelleri JC, Postma MJ, Heeg B. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting. Appl Health Econ Health Policy. 2021 Jul 12. doi: 10.1007/s40258-021-00666-0. Epub ahead of print. PMID: 34250585.


8: Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Xu J, Zhang Q, Dalal M. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States. Cancer Treat Res Commun. 2021;28:100424. doi: 10.1016/j.ctarc.2021.100424. Epub 2021 Jun 18. PMID: 34198039.


9: Prajapati PB, Bagul N, Kalyankar G. Implementation of DoE and Risk-Based Enhanced Analytical Quality by Design Approach to Stability Indicating RP-HPLC Method for Stability Study of Bosutinib. J AOAC Int. 2021 Jun 8:qsab078. doi: 10.1093/jaoacint/qsab078. Epub ahead of print. PMID: 34100929.


10: Liu QS, Ass'ad NA, Arana Yi C. Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review. Clin Case Rep. 2021 May 7;9(5):e03164. doi: 10.1002/ccr3.3164. PMID: 34094551; PMCID: PMC8145267.


11: Wall TP, Crowley PD, Buggy DJ. The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro. Anticancer Res. 2021 Jun;41(6):2835-2840. doi: 10.21873/anticanres.15064. PMID: 34083273.


12: Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 Aug 1;96(8):1000-1007. doi: 10.1002/ajh.26238. Epub 2021 May 28. PMID: 33991360.


13: Hall KH, Brooks A, Waller EK. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. Am J Hematol. 2021 Aug 1;96(8):E293-E295. doi: 10.1002/ajh.26231. Epub 2021 May 25. PMID: 33971041.


14: Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, Ohkura M, Ono C, Viqueira A, Cortes JE, Brümmendorf TH. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021 Jul;114(1):65-78. doi: 10.1007/s12185-021-03144-4. Epub 2021 Apr 13. PMID: 33851349.


15: Hirasawa T, Kikuchi M, Shigeta K, Takasaki S, Sato Y, Sato T, Ogura J, Onodera K, Fukuhara N, Onishi Y, Maekawa M, Mano N. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in- source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. Biomed Chromatogr. 2021 Aug;35(8):e5124. doi: 10.1002/bmc.5124. Epub 2021 Apr 18. PMID: 33772839.


16: Takakuwa T, Sakai R, Koh S, Okamura H, Nanno S, Nakashima Y, Nakane T, Koh H, Hino M, Nakamae H. High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib. Clin Case Rep. 2021 Jan 13;9(3):1344-1349. doi: 10.1002/ccr3.3770. PMID: 33768841; PMCID: PMC7981704.


17: Abumiya M, Takahashi N, Takahashi S, Yoshioka T, Kameoka Y, Miura M. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy. Sci Rep. 2021 Mar 18;11(1):6362. doi: 10.1038/s41598-021-85757-7. PMID: 33737618; PMCID: PMC7973796.


18: Muresan B, Mamolo C, Cappelleri JC, Leip E, Viqueira A, Heeg B. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2021 May;37(5):801-809. doi: 10.1080/03007995.2021.1896489. Epub 2021 Apr 2. PMID: 33733983.


19: Hu S, Xie D, Zhou P, Liu X, Yin X, Huang B, Guan H. LINCS gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1. Int J Mol Med. 2021 May;47(5):72. doi: 10.3892/ijmm.2021.4905. Epub 2021 Mar 11. PMID: 33693953; PMCID: PMC7952247.


20: Kleinveld DJB, Botros L, Maas MAW, Kers J, Aman J, Hollmann MW, Juffermans NP. Bosutinib reduces endothelial permeability and organ failure in a rat polytrauma transfusion model. Br J Anaesth. 2021 May;126(5):958-966. doi: 10.1016/j.bja.2021.01.032. Epub 2021 Mar 6. PMID: 33685634; PMCID: PMC8258973.